New pill for hepatitis B added to current treatment
Part of Digestive system, Infections clinical trials.
This study tests a new pill called ZM-H1505R added to your current daily oral antiviral to see if it can better control hepatitis B virus. It's for people whose virus is still active despite standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been on a standard oral antiviral (like entecavir, tenofovir disoproxil, tenofovir alafenamide, or tenofovir maleate) for at least 1 year, and the same one for at least 6 months
- Your hepatitis B virus DNA level is 50 IU/mL or higher (virus is still active despite treatment)
- You have a positive HBeAg test (meaning the virus is actively reproducing)
- You do not have advanced liver scarring or cirrhosis, and you do not have liver cancer or other serious liver diseases
- You are willing to use effective birth control during the study and for 28 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.